Total votes: 7

Consolidated cash position was approx. $21.4 million in December 2011

Alchemia is a biotechnology company with particular expertise in chemistry. They have one product approved and being marked - synthetic heparin.


Upcoming Events:
- Phase III colorectal cancer trial
- Phase II cancer stem cell program

Highlights:
- revenues for synthetic Heparin have begun
- Positive results for colorectal cancer Phase II trial
- the HyACTdrug delivery platform Alchemia's antithrombotic drug, generic heparin, is the Company's primary opportunity and targets the multi-billion dollar heparin-drug market with Fondaparinux.

Fondaparinux is may have a superior safety and efficacy relative to the market leading drug Lovenoxand. Alchemia's product is very difficult to synthesize and therefore it is possible that there will be limited competition from other generics.

HA-irinotecan is Alchemia's most advanced anticancer product. It  HA-irinotecan not only allowed more cycles of irinotecan to be administered to colon cancer patients, but also produced significant disease control and a doubling in progression free survival.

The HyACTdrug delivery platform presents multiple product opportunities. HyACTimproves the delivery of chemotherapeutic agents to cancer cells. HyACTboosts drug efficacy and reduces unwanted side effects. The technology also has applications and is applicable to other therapeutic agents from small molecule cytotoxics to much larger biologics (i.e. monoclonal antibodies).

Possible Competitors

Apicore LLC has filed for a possible equivalent generic heparin with the FDA